These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 30032807)

  • 1. The challenges of assessing effectiveness of lacosamide using electronic medical record databases.
    Kalilani L; Halpern R; Seare J; Dedeken P
    Epilepsy Behav; 2018 Aug; 85():195-199. PubMed ID: 30032807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of adjuvant lacosamide: The role of clinical characteristics and mechanisms of action of concomitant AEDs.
    Neal A; D'Souza W; Hepworth G; Lawn N; Cook M; Nikpour A
    Epilepsy Behav; 2018 Mar; 80():25-32. PubMed ID: 29396359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term efficacy and safety of lacosamide and levetiracetam monotherapy in elderly patients with focal epilepsy: A retrospective study.
    Del Bianco C; Placidi F; Liguori C; Mari L; Ulivi M; Ornello R; Pisani A; Mercuri NB; Izzi F
    Epilepsy Behav; 2019 May; 94():178-182. PubMed ID: 30959275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective, multicenter, noninterventional study in Taiwan to evaluate the safety and tolerability of lacosamide as adjunctive therapy for epilepsy in clinical practice.
    Wu T; Chuang YC; Huang HC; Lim SN; Hsieh PF; Lee WT; Cheng MY; Tsai MH; Jou SB; Chang CW; Hsieh HY; Du X; Hellot S; McClung C; Hung C
    Epilepsy Behav; 2020 Dec; 113():107464. PubMed ID: 33152580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality of life, mood and seizure control in patients with brain tumor related epilepsy treated with lacosamide as add-on therapy: A prospective explorative study with a historical control group.
    Maschio M; Zarabla A; Maialetti A; Fabi A; Vidiri A; Villani V; Giannarelli D
    Epilepsy Behav; 2017 Aug; 73():83-89. PubMed ID: 28623754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term exposure and safety of lacosamide monotherapy for the treatment of partial-onset (focal) seizures: Results from a multicenter, open-label trial.
    Vossler DG; Wechsler RT; Williams P; Byrnes W; Therriault S;
    Epilepsia; 2016 Oct; 57(10):1625-1633. PubMed ID: 27528101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lacosamide and concomitant use of antiepileptic and other medications in a US population - A retrospective cohort study.
    Kalilani L; Lu C; Pierre-Louis B; Gold M
    Epilepsy Behav; 2017 Jul; 72():51-57. PubMed ID: 28575767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Healthcare resource utilization and costs before and after lacosamide initiation as adjunctive therapy among patients with epilepsy in the United States.
    Fishman J; Martin M; Labiner DM; Lew CR; Johnson BH
    Epilepsy Behav; 2019 Oct; 99():106331. PubMed ID: 31399339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of lacosamide on depression and anxiety symptoms in patients with focal refractory epilepsy: A prospective multicenter study.
    Rocamora R; Ley M; Molins A; Toledo M; Sansa G; Bertol V; Becerra JL; Carreño M; Mauri JÁ
    Epilepsy Behav; 2018 Feb; 79():87-92. PubMed ID: 29253680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient characteristics and treatment patterns in patients with newly diagnosed epilepsy: A US database analysis.
    Faught E; Helmers S; Thurman D; Kim H; Kalilani L
    Epilepsy Behav; 2018 Aug; 85():37-44. PubMed ID: 29906700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A noninterventional study evaluating the effectiveness and safety of lacosamide added to monotherapy in patients with epilepsy with partial-onset seizures in daily clinical practice: The VITOBA study.
    Runge U; Arnold S; Brandt C; Reinhardt F; Kühn F; Isensee K; Ramirez F; Dedeken P; Lauterbach T; Noack-Rink M; Mayer T
    Epilepsia; 2015 Dec; 56(12):1921-30. PubMed ID: 26526971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of treatment with lacosamide: Postmarketing experience from the Middle East region.
    Arabi M; Alsaadi T; Nasreddine W; Al-Hashel J; Dirani M; Beydoun A
    Epilepsy Behav; 2018 Jul; 84():118-121. PubMed ID: 29778846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjunctive lacosamide--5 years' clinical experience.
    Stephen LJ; Kelly K; Parker P; Brodie MJ
    Epilepsy Res; 2014 Oct; 108(8):1385-91. PubMed ID: 25064538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lacosamide as first add-on or conversion monotherapy: A retrospective real-life study.
    Casciato S; Quarato PP; Gialluisi A; D'Aniello A; Mascia A; Grammaldo LG; Di Gennaro G
    Epilepsy Behav; 2021 Sep; 122():108128. PubMed ID: 34229159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term efficacy and safety of lacosamide monotherapy in the treatment of partial-onset seizures: A multicenter evaluation.
    Giráldez BG; Toledano R; García-Morales I; Gil-Nagel A; López-González FJ; Tortosa D; Ojeda J; Serratosa JM
    Seizure; 2015 Jul; 29():119-22. PubMed ID: 26076854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perampanel and lacosamide monotherapy in pediatric patients with newly diagnosed focal epilepsy: A prospective study evaluating efficacy, tolerability, and behavior.
    Zhou R; Qu R; Liu M; Huang DP; Zhou JY; Chen Y; Chen XQ
    Epilepsy Behav; 2023 Sep; 146():109353. PubMed ID: 37481960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and tolerability of immediate switch from sodium channel blockers to Lacosamide.
    Talha Özgün O; Kandemir Yılmaz M; Mert Atmaca M; Keskin Güler S; Buluş E; Duman A; Çelebi Ö; Gürses C
    Epilepsy Behav; 2023 Aug; 145():109355. PubMed ID: 37473655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lacosamide in monotherapy in BTRE (brain tumor-related epilepsy): results from an Italian multicenter retrospective study.
    Mo F; Meletti S; Belcastro V; Quadri S; Napolitano M; Bello L; Dainese F; Scarpelli M; Florindo I; Mascia A; Pauletto G; Bruno F; Pellerino A; Giovannini G; Polosa M; Sessa M; Conti Nibali M; Di Gennaro G; Gigli GL; Pisanello A; Cavallieri F; Rudà R
    J Neurooncol; 2022 May; 157(3):551-559. PubMed ID: 35397759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LACONORTE study: Efficacy and security of lacosamide as first add-on therapy for focal-onset epilepsy in real-life setting.
    Muñoz-Lopetegi A; López-González FJ; Rodríguez-Osorio X; Pato Pato A; Bellas Lamas P; Abella-Corral J; Castro Vilanova MD; Garea MJ; Gil López JA; Ruiz-Martínez J; Poza JJ
    Epilepsy Res; 2018 Sep; 145():51-54. PubMed ID: 29890341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical impact of the dose and blood concentration of lacosamide in Japanese pediatric patients with epilepsy: A cohort study.
    Ishikawa N; Eguchi Y; Izumo H; Tateishi Y; Tani H; Kobayashi Y; Okada S
    Epilepsy Behav; 2022 Apr; 129():108614. PubMed ID: 35203014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.